Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Community Acquired Bacterial Pneumonia
Conditions
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Trial Timeline
Jan 1, 2011 → May 1, 2014
NCT ID
NCT01602874About Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin
Tigecycline + Tigecycline + cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside + CAP: Ceftriaxone, plus if applicable oral clarithromycin is a phase 3 stage product being developed by Pfizer for Community Acquired Bacterial Pneumonia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01602874. Target conditions include Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00914888 | Phase 3 | Withdrawn |
| NCT01602874 | Phase 3 | Withdrawn |
Competing Products
17 competing products in Community Acquired Bacterial Pneumonia